TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21350839
Drug: rAd2p53 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: rAd2p53 gene therapy + RT (n = 22)
Study: 17419956
Drug: Pegaptanib sodium
Normalized name: Pegaptanib Sodium
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegaptanib sodium (intra-ocular injection) for 54 weeks, followed by re-randomization to continue or discontinue treatment.
Study: 15983290
Drug: Amlodipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2.5 to 10 mg/d)
Study: 15983290
Drug: Lisinopril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10 to 40 mg/d)
Study: 9489629
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment with recombinant alpha interferon (IFN-alpha)
Study: 9489629
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of chemotherapy courses prior to autologous PBSC transplantation
Study: 11171785
Drug: Intensive lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive lipid-lowering therapy
Study: 2506608
Drug: Alprazolam (AL;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (AL; 0.25 mg)
Study: 2506608
Drug: Lorazepam (LO;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (LO; 1 mg)
Study: 1176972
Drug: Drug alleged
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug alleged to induce flashbacks (specific drug not mentioned)
Study: 30732940
Drug: Ritonavir-boosted lopinavir
Normalized name: lopinavir / ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir-boosted lopinavir (800 mg lopinavir plus 200 mg ritonavir once daily or 400 mg plus 100 mg twice daily)
Study: 16460251
Drug: 0.2% CHX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% CHX spray
Study: 16460251
Drug: 0.03% TRN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% TRN spray
Study: 16460251
Drug: 0.05% CPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% CPC spray
Study: 16460251
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (negative control)
Study: 15166643
Drug: alanine infusion
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alanine infusion (control)
Study: 11813896
Drug: Azithromycin at
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin at a dose of 10 mg/kg once daily for 3 days, repeated weekly for up to 12 weeks
Study: 11813896
Drug: Azithromycin at
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin at a dose of 10 mg/kg once daily for 3 days for the first week, repeated for 1 day a week for the following 11 weeks
Study: 11813896
Drug: Pseudoephedrine hydrochloride
Normalized name: Pseudoephedrine Hydrochloride
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pseudoephedrine hydrochloride (PHCl), 4 mg/kg, 3 times daily for up to 12 weeks
Study: 3140572
Drug: GnRH-agonist (buserelin)
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH-agonist (buserelin) 400 micrograms intranasally once daily
Study: 29325436
Drug: Schema Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schema Therapy
Study: 21247517
Drug: ivabradine 5
Normalized name: ivabradine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine 5 or 7.5 mg/day
Study: 12610188
Drug: paclitaxel, estramustine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: paclitaxel, estramustine, and oral etoposide (TEE)
Study: 8721467
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg hyperbaric lignocaine 5%
Study: 8721467
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg hyperbaric lignocaine 5%
Study: 29019899
Drug: gynecological laparoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: gynecological laparoscopic surgery with mannitol treatment (Group B)
Study: 25822010
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for 3 months (teaching coping skills)
Study: 25822010
Drug: Supportive nondirective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive nondirective therapy (supportive listening)
Study: 25822010
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) after excluding subjects on >20 mg/d prednisone equivalent (n = 34)
Study: 21059778
Drug: Hydrocortisone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (50 mg intravenous every six hours until hemodynamic stability, followed by tapering over eight days)
Study: 17701167
Drug: Control (multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (multivitamin tablet Vitamineral)
Study: 9527202
Drug: Reduced prime
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced prime (RP) volume (600 to 800 mL)
Study: 9527202
Drug: Full prime
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full prime (FP) volume (1,400 mL of Plasmalyte solution)
Study: 2908258
Drug: Fansimef (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fansimef (1 tablet containing 250 mg mefloquine + 500 mg sulfadoxine + 25 mg pyrimethamine per week)
Study: 23816039
Drug: Phytosterol tablets
Normalized name: phytosterols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterol tablets 900 mg twice daily
Study: 23816039
Drug: Red yeast
Normalized name: red yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red yeast rice (RYR) 1800 mg twice daily
Study: 21430512
Drug: Tendon gliding
Normalized name: Bos taurus tendon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tendon gliding exercises with conventional treatments
Study: 21430512
Drug: Nerve gliding
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve gliding exercises with conventional treatments
Study: 21430512
Drug: Conventional treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatments (splint and paraffin therapy)
Study: 20142790
Drug: Soy isoflavone
Normalized name: soy isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavone tablets (80 or 120 mg/d)
Study: 20142790
Drug: Soy isoflavone
Normalized name: soy isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavone treatment
Study: 3060967
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antibiotic prophylaxis)
Study: 2462383
Drug: 400 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micrograms albuterol
Study: 2462383
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg albuterol
Study: 2462383
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg albuterol
Study: 3511776
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg albuterol
Study: 8061901
Drug: rIFN‐gamma 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN‐gamma 1.8 mg
Study: 8061901
Drug: rIFN‐gamma 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN‐gamma 0.2 mg and 0.6 mg
Study: 3421209
Drug: control (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: control (18 vegetable-oil capsules)
Study: 17168363
Drug: Focal radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal radiotherapy (20‐24 Gy) in accelerated hyperfractionation (1.3‐1.5 Gy, twice a day, at 5‐hr interval)
Study: 8733683
Drug: 4 g/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/m2 cyclophosphamide (CY)
Study: 8733683
Drug: 7 g/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g/m2 cyclophosphamide (CY)
Study: 1929094
Drug: Povidone-iodine 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Povidone-iodine 5% preparation
Study: 7075329
Drug: Father treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Father treatment
Study: 7075329
Drug: Mother treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mother treatment
Study: 7075329
Drug: Treatment (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (both father and mother)
Study: 31601449
Drug: Total nuts
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total nuts (10+ g/day)
Study: 30672303
Drug: High-intensity laser
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity laser therapy + exercise therapy
Study: 30672303
Drug: Sham-laser +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-laser + exercise therapy
Study: 26498439
Drug: Proton radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton radiation therapy (PRT)
Study: 24368307
Drug: CNTF‐3 low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNTF‐3 low-dose implant
Study: 24368307
Drug: CNTF‐3 high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNTF‐3 high-dose implant
Study: 24368307
Drug: CNTF‐4 high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNTF‐4 high-dose implant
Study: 20883227
Drug: Lisinopril 40
Normalized name: lisinopril 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 40 mg
Study: 18974967
Drug: Lisinopril 60
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril 60 mg
Study: 14725952
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg propoxyphene napsylate
Study: 14725952
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg propoxyphene napsylate
Study: 14725952
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg propoxyphene napsylate
Study: 14725952
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg morphine sulfate
Study: 11577993
Drug: (1‐‐>3)‐beta‐D‐glucan inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: (1‐‐>3)‐beta‐D‐glucan inhalation
Study: 28207540
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg mifepristone
Study: 11360607
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg mifepristone plus 7.5 mg anordrin
Study: 11360607
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg mifepristone plus 5 mg anordrin
Study: 2278323
Drug: Midazolam 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.3 mg/kg, continuous infusion, with nitrous oxide in oxygen
Study: 2278323
Drug: Midazolam 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.3 mg/kg, continuous infusion, with nitrous oxide in oxygen (600 ng/litre)
Study: 2278323
Drug: Midazolam 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.3 mg/kg, continuous infusion, with oxygen in air (600 ng/litre)
Study: 2278323
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide in combination with midazolam
Study: 28987525
Drug: Trimethoprim-sulfamethoxazole (320/1,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (320/1,600 mg twice daily for 7 days)
Study: 27465353
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of adrenaline ± verapamil in the distal coronary bed through a perfusion balloon or selective microcatheter
Study: 24105084
Drug: Embrace device
Normalized name: LANCET,EMBRACE DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Embrace device treatment
Study: 18188105
Drug: Intravenous ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ethanol infusion (EtOH)
Study: 18188105
Drug: Scheduled-dose diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled-dose diazepam (BENZO)
Study: 11086638
Drug: Heparin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin infusion for at least 5 days
Study: 1468246
Drug: Oral sulodexide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sulodexide (2 capsules of 250 lipoproteinolipase releasing units twice daily)
Study: 1468246
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 identical capsules twice daily)
Study: 6475654
Drug: Frusemide with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide with potassium supplements (48 mmol/day)
Study: 6475654
Drug: Potassium-sparing diuretic
Normalized name: Potassium-sparing diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium-sparing diuretic
Study: 3097108
Drug: Double-blind food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind food challenge with lyophilized food in capsules or food mixed in broth
Study: 3097108
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (300 mg 30 minutes before food challenge)
Study: 31023398
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment (three commonly prescribed antidepressants)
Study: 30392345
Drug: Early enteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early enteral nutrition (EEN) combined with parenteral nutrition (PN)
Study: 22425474
Drug: Inpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient treatment based on cognitive behavior therapy for 4 weeks
Study: 15778428
Drug: 1 mg/kg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg/week subcutaneous efalizumab for 12 weeks
Study: 15778428
Drug: 2 mg/kg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg/week subcutaneous efalizumab for 12 weeks
Study: 3968617
Drug: Supplementary calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementary calcium to 21 mmol/L (Group B)
Study: 3968617
Drug: Further calcium
Normalized name: HOMOSALATE 10 g in 100 mL / OCTOCRYLENE 7 g in 100 mL / OCTISALATE 5 g in 100 mL / AVOBENZONE 3 g in 100 mL TOPICAL LOTION [CO-BB-54431 Featuring You Hydrating Skin Enhancing Tint SPF30-270 FURTHER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Further calcium supplementation to 31.2 mmol/L (Group C)
Study: 3968617
Drug: Milk with
Normalized name: BETTERMILK with Glytactin 10PE Powder for Suspension (Orange Creme)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk with calcium content 31.2 mmol/L and phosphorus supplementation to 15.7 mmol/L (Group D)
Study: 24852701
Drug: Sildenafil 100
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100 mg 1 hour before sexual intercourse
Study: 21380565
Drug: Conventional temperature
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional temperature management using antipyretic medication and surface cooling (active control group)
Study: 16353044
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg/day, n=20)
Study: 16353044
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg/day, n=18)
Study: 8941005
Drug: Oral medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medroxyprogesterone acetate (MPA) treatment at doses of 600, 800 or 1200 mg/day
Study: 8941005
Drug: Oral medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medroxyprogesterone acetate (MPA) treatment
Study: 1338084
Drug: Hydrochlorothiazide +
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide + Amiloride (diuretic)
Study: 1338084
Drug: Supplementary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementary treatment (beta-blocker to diuretic, or vice versa)
Study: 1338084
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active treatment regimens
Study: 6372360
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg PGE2 pessary
Study: 6372360
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg PGE2 pessary
Study: 6372360
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg PGE2 pessary
Study: 25786769
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg q.d.
Study: 25786769
Drug: Esomeprazole 10
Normalized name: esomeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 10 mg q.d.
Study: 21999631
Drug: Nevirapine (NVP)
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine (NVP) 200 mg twice daily
Study: 21999631
Drug: Ritonavir-boosted atazanavir
Normalized name: atazanavir and ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir-boosted atazanavir (ATV/r) 300/100 mg once daily
Study: 18456465
Drug: Azithromycin extended
Normalized name: azithromycin Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin extended release (AZ‐ER) 2g single dose
Study: 18456465
Drug: Azithromycin immediate
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin immediate release (AZ‐IR) 500mg daily for 3 days
Study: 9186076
Drug: Lisinopril (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (n = 13)
Study: 9488243
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS and Lisinopril
Study: 8108538
Drug: Intra-articular steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular steroids
Study: 23742737
Drug: nabiximols (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: nabiximols (oral mucosal spray containing cannabinoids)
Study: 16636857
Drug: Sublingual androstenediol
Normalized name: androstenedione
DrugBank: Androstenedione (DB01536)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual androstenediol (SL-DIOL) with exercise (EX)
Study: 16636857
Drug: Sublingual androstenediol
Normalized name: androstenedione
DrugBank: Androstenedione (DB01536)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual androstenediol (SL-DIOL) without exercise (Rest)
Study: 16636857
Drug: Sublingual androstenediol
Normalized name: androstenedione
DrugBank: Androstenedione (DB01536)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual androstenediol (SL-DIOL)
Study: 9005501
Drug: IHB before
Approvals — FDA: no, EMA: no, PMDA: no
Description: IHB before incision using 0.25 ml/kg bupivacaine 0.5%
Study: 9005501
Drug: IHB after
Approvals — FDA: no, EMA: no, PMDA: no
Description: IHB after incision using 0.25 ml/kg bupivacaine 0.5%
Study: 9005501
Drug: IHB before
Approvals — FDA: no, EMA: no, PMDA: no
Description: IHB before incision with 0.25 ml/kg of serum
Study: 9005501
Drug: IHB after
Approvals — FDA: no, EMA: no, PMDA: no
Description: IHB after incision with 0.25 ml/kg of serum
Study: 8151594
Drug: Misoprostol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (400 micrograms oral dose)
Study: 29480182
Drug: Sequential memory
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential memory training after stationary cycling (SEQ)
Study: 28199799
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g protein hydrolysate
Study: 21381272
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment options
Study: 2773628
Drug: Ranitidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (50 mg)
Study: 391625
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of oxprenolol 80 mg + chlorthalidone 10 mg given once daily
Study: 391625
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of oxprenolol 80 mg + chlorthalidone 10 mg given b.i.d.
Study: 31610616
Drug: Gabapentin 600
Normalized name: gabapentin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 600 mg oral, 1 hour preprocedure
Study: 30298469
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus cisplatin (GC) as first-line chemotherapy
Study: 30298469
Drug: Validation dataset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Validation dataset of patients receiving GC therapy
Study: 18431091
Drug: Ergocalciferol 50,000
Normalized name: ergocalciferol 50,000 intl units oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergocalciferol 50,000 IU once weekly for 3 months
Study: 14681961
Drug: Pronoran (piribedil)
Normalized name: piribedil
DrugBank: Piribedil (DB12478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pronoran (piribedil) combined with levodopa, dosage 50-150 mg daily for 6 months
Study: 7029740
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of metoprolol tartrate 100 mg and chlorthalidone 25 mg
Study: 2270941
Drug: Lente insulin
Normalized name: lente insulin, pork
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lente insulin
Study: 24942594
Drug: 0.2% E6005
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% E6005 ointment
Study: 18083473
Drug: Preoperative intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative intravenous (IV) 50 mg flurbiprofen (group F)
Study: 16216607
Drug: Magnetocardiography (MCG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetocardiography (MCG) at 40 Hz
Study: 16216607
Drug: Magnetocardiography (MCG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetocardiography (MCG) for root mean square of the last 40 milliseconds of atrial signal
Study: 29518425
Drug: Montelukast (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (20 mg twice daily)
Study: 29518425
Drug: LTE4 inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTE4 inhalation